TABLE 1 General characteristics of the two groups#
CharacteristicsLinezolid therapy groupControl groupTotal
Subjects n333265
Age years44 (18–64)43 (18–63)44 (18–64)
Male sex22 (66.7)21 (65.6)43 (66.2)
Body mass index kg·m−219.5 (12–30)19.6 (12–30)19.5 (12–30)
With comorbidity
 Diabetes6 (18.2)6 (18.8)12 (18.5)
 Chronic obstructive pulmonary disease3 (9.1)4 (12.5)7 (10.8)
 Bronchiectasis8 (24.2)9 (28.1)17 (26.2)
 Tuberculous pleurisy6 (18.2)5 (15.6)11 (16.9)
 Respiratory failure7 (21.2)6 (18.8)13 (20)
Decreased albumin10 (30.3)9 (28.1)19 (29.2)
Lung cavities
 Unilateral16 (48.5)15 (46.9)31 (47.7)
 Bilateral17 (51.5)17 (53.1)34 (52.3)
Course of disease
 ≥1 year <5 years before randomisation19 (57.6)18 (56.2)37 (56.9)
 ≥5 years before randomisation14 (42.4)14 (43.8)28 (43.1)
Previous treatment
 ≥1 year <5 years before randomisation21 (66.7)22 (68.7)38 (67.7)
 ≥5 years before randomisation11 (33.3)10 (31.3)21 (32.3)
Susceptibility test results resistance
 Streptomycin30 (90.9)30 (93.8)60 (92.3)
 Isoniazid33 (100)32 (100)65 (100)
 Rifampin33 (100)32 (100)65 (100)
 Ethambutol29 (87.9)30 (93.8)59 (90.8)
 Ofloxacin33 (100)32 (100)65 (100)
 Amikacin26 (78.8)25 (78.1)51 (78.5)
 Capreomycin25 (75.8)25 (78.1)50 (76.9)
Background regimen
 Prothionamide, pyrazinamide, moxifloxacin or  gatifloxacin or levofloxacin, para-aminosalicylic acid33 (100)32 (100)65 (100)
 Capreomycin or amikacin18 (54.5)17 (53.1)35 (53.8)
 Clofazamine22 (66.7)20 (59.4)42 (64.6)
 Clarithromycin18 (54.5)19 (51.5)37 (56.9)
  • Data are presented as n (%) or mean (minimum–maximum), unless otherwise stated. #: there were no significant between-group differences; : respiratory failure was defined as arterial oxygen tension lower than 60 mmHg by arterial blood gas analysis.